早期非小细胞肺癌立体定向消融放疗后最佳影像监测:一项国际德尔菲共识研究的结果
该国际德尔菲共识研究邀请31名胸部放射肿瘤与放射科意见领袖(11人参与,含9名放射肿瘤医师和2名放射科医师),经3轮德尔菲流程、以≥75%同意/不同意阈值得出共识。共识推荐随访常规行胸部CT,第1年3、6、12个月检查、第2年每6个月、第3至5年每年检查;疑似局部复发时强烈推荐FDG PET/CT;CT可疑局部复发的征象包括侵犯邻近结构、边缘膨隆、持续增大、肿块样生长、球形生长、头尾方向生长及空气支气管征消失。
要点
- 随访应常规行胸部CT,第1年3、6、12个月,第2年每6个月,第3至5年每年。
- 疑似局部复发时强烈推荐FDG PET/CT;无此怀疑时常规FDG PET/CT证据有限。
- CT提示局部复发的征象包括侵犯邻近结构、边缘膨隆、持续增大、肿块样生长等。
核心结论
- 该共识为早期非小细胞肺癌患者SABR后管理中的不确定领域提供了国际专家共识推荐。
研究设计与样本
- 国际德尔菲共识研究,邀请31名胸部放射肿瘤与放射科意见领袖,11人参与(9名放射肿瘤医师、2名放射科医师),经3轮德尔菲流程,采用5点Likert量表评分,以≥75%同意/不同意作为共识阈值。
关键影像表现/征象
- CT提示局部复发的征象包括侵犯邻近结构、边缘膨隆、持续增大、肿块样生长、球形生长、头尾方向生长及空气支气管征消失。
诊断标准与关键数值
- 共识阈值:≥75%同意/不同意。
- RECIST 1.1标准不足以检测局部复发。
- 应采用经验证数据的正式评分系统对预测局部复发的高危影像特征进行分类。
临床应用与阅片要点
- 随访应常规开具胸部CT。
- 疑似局部复发时强烈推荐FDG PET/CT;否则常规FDG PET/CT证据有限。
- CT检查不推荐在6周时进行,推荐在第1年3、6、12个月,第2年每6个月,第3至5年每年进行。
- 5年后应继续CT检查,但检查频率未达成共识。
- 影像高度可疑且活检不安全/不可行或活检无诊断结果时,可不行病理证实直接行挽救治疗。
局限性
- 邀请31名意见领袖,仅11人接受参与。
- 5年后CT检查频率未达成共识。
- 无局部复发怀疑时,常规FDG PET/CT的指导证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Imaging after stereotactic ablative radiation therapy (SABR) for early-stage non-small cell lung cancer can detect recurrences and second primary lung cancers; however, the optimal follow-up practice of these patients remains unclear. We sought to establish consensus recommendations for surveillance after SABR.
METHODS AND MATERIALS: International opinion leaders in thoracic radiation oncology and radiology were invited to participate (n = 31), with 11 accepting (9 radiation oncologists, 2 radiologists). Consensus-building was achieved using a 3-round Delphi process. Participants rated their agreement/disagreement with statements using a 5-point Likert scale. An a priori threshold of ≥75% agreement/disagreement was required for consensus.
RESULTS: A 100% response rate was achieved and final consensus statements were approved by all participants. The consensus statements were: (1.1) thoracic computed tomography (CT) scans should be ordered routinely in follow-up; (1.2) if there is a suspicion for local recurrence (LR), fludeoxyglucose positron emission tomography/CT scans are strongly recommended. Otherwise, there is limited evidence to guide routine use of fludeoxyglucose positron emission tomography /CT; (1.3) CT imaging is not recommended at 6 weeks, but is recommended at months 3, 6, and 12 in year 1 and then every 6 months in year 2 and annually in years 3 through 5; (1.4) after 5 years, CT imaging should continue, although no consensus was reached regarding the frequency. (2.1) Response Evaluation Criteria in Solid Tumors 1.1 criteria are not sufficient for detecting LR; (2.2) a formal scoring system, informed by validated data, should be used to classify high-risk imaging features predictive of LR; (2.3) CT findings suspicious for LR include: infiltration into adjacent structures, bulging margins, sustained growth, mass-like growth, spherical growth, craniocaudal growth, and loss of air bronchograms. (3) Salvage therapy without pathologic confirmation of recurrence is acceptable if imaging findings are highly suspicious and a biopsy is not safe/feasible or if an attempted biopsy was nondiagnostic.
CONCLUSIONS: These guidelines provide international expert consensus on areas of uncertainty in the management of early-stage non-small cell lung cancer patients after SABR.
引用
- Nguyen TK, Senan S, Bradley JD, et al. Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study. Pract Radiat Oncol. 2017. PMID: 29291965. doi:10.1016/j.prro.2017.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。